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In 1999, a review of the literature for 1966–1997 sug-
gested that ≈1.1 million persons die annually of shigellosis, 
including ≈880,000 in Asia. Our recent review of the litera-
ture for 1990–2009 indicates that ≈125 million shigellosis 
cases occur annually in Asia, of which ≈14,000 are fatal. 
This estimate for illnesses is similar to the earlier estimate, 
but the number of deaths is 98% lower; that is, the lower es-
timate of deaths is associated with markedly reduced case-
fatality rates rather than fewer cases. Shigella spp.–related 
deaths decreased substantially during a period without Shi-
gella spp.–speciﬁ   c interventions. We speculate that non-
speciﬁ  c interventions, e.g., measles vaccination, vitamin A 
supplementation, and improved nutrition, may have led to 
the reduced number of shigellosis-related deaths.
I
n 1999, Kotloff et al. reviewed the literature to estimate 
the global incidence of shigellosis. On the basis of studies 
published during 1966–1997, they estimated ≈1.1 million 
shigellosis-related deaths annually, resulting from ≈164.7 
million cases. Of these, ≈163.2 million cases occurred in 
developing countries, ≈80% of which occurred in Asia (1). 
These high estimates of illness and death have increased in-
terest in identifying interventions, including new vaccines, 
that might reduce these astonishing numbers (2–5).
Several changes have occurred that might have altered 
this incidence. Shigellosis might be increasing because 
of increasing populations in Shigella spp.–endemic areas; 
because of increasing resistance to antimicrobial drugs 
among shigellae, especially in S. dysenteriae type 1 (the 
Shiga bacillus) (6–8); or because of increasing rates of 
HIV infection and AIDS in many countries, which might 
be inﬂ  uencing shigellosis incidence. On the other hand, 
incidence might be decreasing because of improved nutri-
tion in many countries, improved delivery of healthcare in 
some areas, and more widespread use of measles vaccine 
(9,10) and vitamin A supplementation (11), which might 
reduce the severity of intestinal infections. The availability 
of ﬂ  uoroquinolones, often used without prescription, also 
might lead to changing treatment practices because fami-
lies might use antimicrobial drugs earlier during diarrheal 
illness or for other illnesses (12).
Shigellosis incidence might also have changed be-
cause of the overall reduction in diarrhea-related deaths 
through case management, including rehydration therapy 
and proper feeding (13). Because shigellosis is not primar-
ily a dehydrating condition, hydration is not critical for 
patients with dysentery. Nonetheless, the consistent use 
of oral rehydration therapy for diarrhea may reduce illness 
from the persistent effects of repeated episodes of diarrhea, 
which is common in developing counties.
Thus, at the request of the World Health Organiza-
tion, we reviewed the literature for 1990–2009 to estimate 
the current incidence of shigellosis. The earlier study by 
Kotloff et al. attempted to extrapolate from data from de-
veloping countries; however, most of the data were from 
Asia. Because the epidemiology of shigellosis may dif-
fer in Africa, we restricted our review to studies in Asian 
populations.
Materials and Methods
Our review comprised studies identiﬁ  ed  through 
Medline. The initial studies were identiﬁ  ed by a computer 
search of the multilingual scientiﬁ   c literature published 
since 1990. Articles derived by using the keywords Shi-
gella, dysentery, bacillary, and shigellosis were linked with 
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a set of other articles obtained by using the keywords inci-
dence, prevalence, public health, death rate, mortality, sur-
veillance, burden, distribution, and permutations of the root 
word epidemiol-. We conducted searches for each Asian 
country, except Japan and Israel. The resulting cross-linked 
set contained 319 articles, which we culled to 164 articles 
that were relevant to the goal of the search. Additional 
sources were located through consultations with experts in 
the ﬁ  eld, proceedings of expert meetings, and the ongoing 
Diarrheal Diseases Surveillance Programme of the Interna-
tional Centre for Diarrheal Disease Research, Bangladesh 
(ICDDR,B). To enable comparison over time, we adopted 
the methods of the previous review on shigellosis (1).
We created an algorithm to estimate the number of 
Shigella infections that occurred each year in Asia. In a 
preliminary step, the world’s population was divided into 
4 age strata (0–11 months, 1–4 years, 5–14 years, and >15 
years). Published rates of diarrhea for each of the 4 strata 
were used to estimate the diarrheal disease incidence. An 
increase in the severity of a patient’s illness inﬂ  uences the 
proportion of diarrheal episodes attributable to Shigella spp. 
This correlation can be presumed to strengthen as the pro-
portion of Shigella infections increases because sampling 
progresses from cases of diarrhea detected by household 
surveillance to those among outpatients to persons admit-
ted to hospital (14). Thus, we subdivided the total diarrheal 
disease incidence into these 3 settings: estimates of mild 
cases in persons who stayed at home; more severe cases 
needing care at a clinic but not hospitalization; and cases 
requiring hospitalization.
The total number of diarrhea cases attributable to 
shigellosis was calculated for the <1-year and 1–4-year 
age groups by multiplying the number of diarrhea cases 
in the 2 settings (community and treatment facilities) by 
the percentage of diarrhea cases from which Shigella spp. 
were isolated (Table 1). For older children and adults, we 
calculated total cases by multiplying the median percent-
ages of diarrhea cases attributable to shigellosis in per-
sons 5–14 years and >15 years of age by the number of 
diarrhea cases in these 2 age groups according to clinical 
setting (Table 2).
We adopted the estimates of Kosek et al. (15) to cal-
culate the number of diarrhea episodes per person per year 
within countries in Asia (Table 1). These estimates were 
based on the review of 13 longitudinal studies of stable 
populations in 8 countries in Asia, where active surveil-
lance was conducted during 1984–1995.
We estimated the proportion of diarrheal episodes in 
each stratum that can be attributed to shigellosis by analyz-
ing only studies in which surveillance was conducted since 
1990 and that used microbiologic conﬁ  rmations to report 
the percentage of Shigella spp.–related diarrhea cases for 
the speciﬁ  ed age group. An overall median percentage of 
shigellosis was then calculated for each stratum and multi-
plied by the total number of diarrheal cases in the stratum 
to derive the number of shigellosis cases in each stratum. 
In addition to the median, a weighted mean with 95% con-
ﬁ  dence intervals (CIs) was calculated for these analyses by 
using Freeman-Tukey transformed proportions. Weights 
used were equal to the inverse standard errors of these 
transformed proportions (18,19). The numbers of shigello-
sis cases were added to give an overall estimate of shigello-
sis-related illness. Case-fatality rates (CFRs) for persons 
hospitalized with Shigella infection at the ICDDR,B hos-
pital were used to calculate age-speciﬁ  c rates of Shigella 
spp.–associated death. This hospital treats >100,000 diar-
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Table 1. Estimated annual number of diarrheal episodes in children 0–4 years of age, Asia, 1990–2009 
Characteristic
Age group 
0–11 mo  1–4 y  0–4 y 
Total population, × 1,000  78,533  282,719  361,252 
No. diarrheal episodes/child/y (15) 3.2 2.3
Total diarrheal episodes, × 1,000  251,306  650,252  901,559 
  At home (14,16) 221,651  597,583  819,234 
  At treatment facility (14,16) 29,655  52,670  82,325 
  In  outpatient  department  25,884  51,370  77,254 
  Hospitalized  3,771  1,300  5,071 
Median caused by shigellosis, %
 At  home* 4.4%
 In  treatment  facility† 5.8 9.4
Weighted mean caused by shigellosis, % (95% confidence interval) 5.1 (4.0–5.7)
No. shigellosis cases
  At home, × 1,000 39,669
  In treatment facility, × 1,000 1,720 4,951 6,671
Total, × 1,000 46,340
95% confidence interval of weighted mean, × 1,000 44,924–57,316
*Online Technical Appendix Table 1 (www.cdc.gov/EID/content/16/11/1718-Techapp.pdf). 
†Online Technical Appendix Table 2. RESEARCH
rhea patients annually and is the same hospital used for 
CFRs in the earlier study.
Illness was expressed as episodes of diarrhea per 
person-year from which shigellae were recovered. Studies 
were included in the death estimates if deaths caused by 
Shigella spp. could be ascertained through active surveil-
lance. The review comprised prospective and retrospective 
studies but not studies based on vital statistics only. Death 
was considered to have been caused by diarrhea only if di-
arrhea was listed as the primary cause.
Results
Approximately 3,938,020,000 persons resided in Asia 
during 2005. This estimate included 78,533,000 infants 
<1 year of age and 361,252,000 children 1–4 years of age 
(20,21).
Shigellosis Incidence
The median frequency of Shigella spp. isolation from 
diarrheal cases in the community in children 0–4 years of 
age was 4.4% (range 3.1%–13.4%; weighted mean 5.1%, 
95% CI 4.4%–5.7%). Because only 1 study broke this rate 
down into the <1-year and 1–4-year ranges, the median of 
the 2 values for the combined range was calculated. The 
median frequencies of Shigella spp. isolation rates from 
persons with diarrhea reporting to the treatment facilities 
were 5.8% (range 2.4%–9.3%) among children <1 year of 
age and 9.4% (range 2.4%–23.5%) among children 1–4 
years of age. The weighted mean of the combined group 
was 6.6% (95% CI 6.0%–7.2%). Details of these studies 
are found in online Technical Appendix Tables 1, 2 (www.
cdc.gov/EID/content/16/11/1718-Techapp.pdf).
Approximately 39,669,000 (weighted mean 
45,980,000, 95% CI 39,669,000–51,389,000) shigellosis 
cases occurred in children <5 years of age in the com-
munity and 6,671,000 (weighted mean 5,433,000, 95% 
CI 5,256,000–5,927,000) in treatment facilities, totaling 
46,717,000 (95% CI 44,924,000–57,316,000) cases among 
Asian children <5 years of age annually. The proportions 
of cases with shigellosis are detailed in online Technical 
Appendix Tables 1, 2.
The median percentage of diarrhea in the commu-
nity was 4.0% (range 1.6%–13.5%; weighted mean 4.6%, 
95% CI 4.0%–5.1%). The median percentages for patients 
treated at facilities were ≈11.6% (range 4.7%–17.3%) and 
≈10.7% (range 4.1%–27%) respectively (weighted mean of 
the combined groups 8.3%, 95% CI 7.7–9.0%). (The pro-
portions of shigellosis cases are detailed in online Techni-
cal Appendix Tables 3 and 4.) Shigella infections among 
children 5–14 years of age and persons >15 years of age 
were ≈20,049,000 (95% CI 19,673,000–24,898,000) and 
≈58,576,000 (95% CI 57,726,000–73,057,000), respec-
tively.
We combined the number of shigellosis episodes in all 
age groups. The total annual number of shigellosis cases in 
Asia was ≈125 million (95% CI 122 million–155 million).
Shigellosis-associated Deaths
Median CFRs for hospitalized shigellosis patients <1 
year and 1–4 years of age and patients >5 years of age were 
0.89%, 0.01%, and 0 respectively (Table 3), according to 
data from the ICDDR,B hospital surveillance program dur-
ing 1990–2007. The weighted means for patients <1 and 
1–4 years of age were 0.8% (95% CI 0.5%–1.0%) and 0.1% 
(95% CI 0.02%–0.25%), respectively. No deaths were re-
ported from large studies in other countries in Asia. By us-
ing median CFRs from Bangladesh for these age groups, 
we determined that ≈1,960 shigellosis deaths occurred in 
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Table 2. Shigella spp.–associated diarrhea in older children and adults, Asia, 1990–2009 
Characteristic
Age group, y 
5–14 >15
Population (× 1,000)  742,911  2,833,857 
Diarrhea episodes/person/y (17)* 0.65 0.50
Total diarrhea episodes, × 1,000  482,892  1,416,929 
 At  home  473,234 1,388,590 
  Treatment facility (1)† 9,658  28,339 
Median caused by Shigella spp., % 
 At  home*  44
  At treatment facility†  11.6 10.7
Proportion caused by shigellosis (weighted mean), %
 At  home* 4.6 (4.0–5.1) 
  At treatment facility† 8.3 (7.7–9.0) 
Annual no. episodes of Shigella spp.–associated diarrhea, × 1,000 
 At  home  18,929 55,544 
  At treatment facility  1,120 3,032
Total no. episodes of Shigella spp.–associated diarrhea, × 1,000  20,049  58,576 
95% confidence interval of weighted mean, × 1,000 19,673–24,898 57,726–73,057
*Online Technical Appendix Table 3 (www.cdc.gov/EID/content/16/11/1718-Techapp.pdf). 
†Online Technical Appendix Table 4. Decreasing Shigellosis-related Deaths
Asia among hospitalized patients annually (Table 3). By 
using the 95% CIs, we estimated that the number of deaths 
ranged from 1,347 to 2,595.
A study from Bangladesh found that only 17.8% of 
shigellosis-related deaths occurred in treatment facilities; 
another study from the Gambia reported that only 12% of 
deaths associated with Shigella infection among children 
occurred in a health center (23,24). Thus, the true number 
of shigellosis-associated deaths may be 6–8× higher than 
deaths recorded in the hospital records. Hence, the estimates 
of the in-hospital shigellosis-associated deaths were multi-
plied by a factor of 7 in all age groups to correct for out-of-
hospital mortality. This increased the number of deaths in 
all age groups to ≈13,720 shigellosis-related deaths across 
all the age groups per year in Asia (Table 4).
Discussion
Our review calculated that ≈125 million cases of en-
demic shigellosis occur annually in Asia, of which ≈14,000 
(0.011%) cases result in death. Children <5 years of age are 
at highest risk for Shigella spp.–related illness and death. 
Although this estimate suggests that shigellosis incidence 
is substantial and similar to the earlier estimate, the updated 
death estimate is 98% lower than the estimate by Kotloff et 
al. (1) that used data primarily from the 1980s. Assuming 
that the population of Asia is ≈80% of the total population 
of the developing countries, ≈130 million Shigella infec-
tions and ≈880,000 deaths occurred in Asia according to 
the earlier estimate.
With such a large difference in estimated incidences, 
one estimate may be more accurate than the other. Alter-
natively, Shigella spp.–related deaths may have decreased 
substantially since the 1980s, even in the absence of spe-
ciﬁ  c interventions against shigellosis. We believe the latter 
explanation best explains the large difference in estimates 
of deaths.
The major variable that was lower in our calculations 
was the CFR for hospitalized patients, especially children. 
In the earlier estimate, a CFR of 11% was used from the 
ICDDR,B hospital (24). Recent data from the same hospi-
tal indicate the rate is now ≈0.01% overall and only 0.89% 
for the youngest age group. A recent estimate from Africa 
found a CFR of <1% during an outbreak associated with 
S. dysenteriae, suggesting that this low CFR may not be 
limited to Asia (25).
The decrease in CFRs could be explained by >1 fac-
tor. Case management might have improved, strains might 
be less virulent, or children might be healthier when they 
become infected and therefore have less severe complica-
tions. Case management in the hospital is unlikely to have 
changed substantially, and in fact the increasing resistance 
of current strains to antimicrobial drugs makes case man-
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Table 3. Case-fatality rates for hospitalized patients with Shigella infections, Asia, 1990–2009 
Country Area  Year 
Case-fatality rate by age group
0–11 mo  1–4 y  >5 y 
Bangladesh* Urban/rural 1990–1999  2.73 1.42 0.33
Bangladesh† Urban 2000–2008 1.26 0 0
Bangladesh‡ Rural 2000–2008  0.51 0.02 0
People’s Republic of China (22) Rural  2002  0 0 0
Thailand (22) Rural  2000–2003  0 0 0
Indonesia (22) Rural  2001–2003  0 0 0
Vietnam (22) Urban/rural  2001–2003  0 0 0
Pakistan (22) Rural  2002–2003  0 0 0
Bangladesh (22) Periurban  2002–2004  0 0 0
Median 0.89 0.02 0
Weighted mean, % (95% confidence interval) 0.80 (0.59–1.03) 0.1 (0.02–0.25)
*International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDRB,B) hospital surveillance, 1990–1999. 
†ICDDR,B hospital surveillance (urban), 2000–2008. 
‡ICDDR,B hospital surveillance (rural), 2000–2008. 
Table 4. Estimated annual number of deaths and case-fatality rates for hospitalized persons with Shigella infection, Asia, 1990–2009* 
Characteristic
Age group 
0–11 mo  1–4 y 
No. persons with diarrhea, × 1,000†  3,771  1,300 
No. persons with Shigella infection, × 1,000 (% total persons with diarrhea)†  219 (5.8)  122 (9.4) 
No. Shigella spp.–related deaths (95% CI)  1,949 (1,292–2256)  24 (24–305) 
Case fatality rate, %‡  0.89 0.01
Corrected no. Shigella spp.–related deaths, × 1,000 (95% CI)§ (23,24)  13,643 (9,044–15,792)  168 (168–2,135) 
Total no. Shigella spp.–related deaths (95% CI)  13,811 (9,212–17,927) 
*CI, confidence interval. 
†Table 1. 
‡Table 3. 
§Corrected for out-of-hospital deaths. RESEARCH
agement more difﬁ  cult. Case management in the home may 
have changed, however, because antimicrobial drugs are 
widely available, and families may purchase effective anti-
microbial drugs, e.g., ciproﬂ  oxacin, and begin treatment 
earlier in the course of the illness (12). Virulence of infect-
ing strains could be lower; infections with S. dysenteriae 
type 1 are unusual. During past epidemics with this sero-
type, however, the CFR for S. ﬂ  exneri was as high as it was 
with S. dysenteriae type 1 (24). Thus, virulence is unlikely 
to explain the decrease in the number of deaths.
Improved health of children who become infected ap-
pears to best explain the decreased CFR. Nutritional status 
of children in Bangladesh has continued to improve slowly 
(26). Perhaps more essential is the high proportion receiv-
ing measles vaccine and vitamin A (27). Anecdotally, in 
children dying of shigellosis during the 1980s, postmeasles 
dysentery was often diagnosed, and measles increased the 
severity of diarrhea, including shigellosis (9,10). Measles 
with dysentery is rarely seen now in Bangladesh.
Our review has some limitations. Although we re-
viewed all available published data on shigellosis in Asia 
since 1990, few sites conduct active surveillance for this in-
fection, and only one estimates CFRs. With this large popu-
lation, extrapolating accurately to the entire continent might 
not be possible. Nevertheless, the same methods were used 
in this and the earlier review. The large multicenter study 
on shigellosis in Asia did not record any deaths, suggesting 
that fatalities from shigellosis are not common (22).
Second, the review included only Asia, and the situa-
tion in Africa is possibly (even likely) different (28). The 
higher rates of HIV infection and AIDS and malaria, differ-
ent nutritional deﬁ  ciencies, different rates of measles vac-
cination, and different health systems and civil disturbance 
might suggest higher Shigella spp.–related deaths in Africa. 
Unfortunately, until recently, no long-term surveillance for 
diarrhea has existed in Africa on which to base estimates.
Third, the data in the review were based on microbio-
logic diagnosis of Shigella infections. Although isolation 
of Shigella spp. from fecal samples is the most speciﬁ  c 
diagnostic test for shigellosis, the culture method has lim-
ited sensitivity because of the relatively fastidious nature 
of the organism. Adoption of improved specimen transport 
methods and newer and more sensitive molecular labora-
tory diagnostic methods (e.g., PCR) reportedly having high 
sensitivities may detect more infections (29) but is unlikely 
to alter the death estimates.
The remarkable 98% decrease in deaths from shigello-
sis in the absence of a Shigella spp.–speciﬁ  c intervention 
suggests that other nonspeciﬁ  c interventions have helped to 
lower Shigella spp.–speciﬁ  c deaths. These, we believe, in-
clude measles vaccine, vitamin A supplements, and overall 
improvement in nutrition. Although the ready availability 
of antimicrobial drugs encourages the development of anti-
biotic drug resistance because of frequent abuse, we cannot 
rule out the possibility that the rapid availability of these 
antibiotics (especially ﬂ  uoroquinolones) also have beneﬁ  t-
ed children with dysentery who may be receiving treatment 
more quickly than they previously did.
The ﬁ  ndings from our review may provide lessons re-
garding other infectious diseases. Approximately 50% of 
deaths among children <5 years of age have malnutrition 
as an underlying cause (30). Also, malnutrition and infec-
tion are clearly related, with one leading to the other. By 
reducing rates of other common infections, e.g., measles, 
and improving the nutritional status, including micronutri-
ent nutrition, of children, diseases from other infections, 
such as Shigella spp., may decrease.
The 4 species and numerous serotypes of Shigella spp. 
are a challenge for vaccine developers, but shigellosis re-
mains high, and increasing resistance to antibiotic drugs 
continues to make treatment difﬁ  cult. An effective Shigella 
spp. vaccine may have substantial beneﬁ  ts, but our study 
suggests that Shigella spp.–related deaths can be, and have 
been, substantially reduced with currently available inter-
ventions and that such interventions do not need to be Shi-
gella spp. speciﬁ  c.
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